there are many evidences that human serum paraoxonase activity modifies plasma lipid profile and paraoxonase has an antiatherogenic property. non-selective beta-blockers affect plasma lipid profile too, but they have atherogenic property when patients take these drugs in long term. in this study the effect of propranolol, a non-selective beta-blocker, on paraoxonase activity was investigated. l...

There are many evidences that human serum paraoxonase activity modifies plasma lipid profile and paraoxonase has an antiatherogenic property. Non-selective beta-blockers affect plasma lipid profile too, but they have atherogenic property when patients take these drugs in long term. In this study the effect of propranolol, a non-selective beta-blocker, on paraoxonase activity was investigated. L...

There are many evidences that human serum paraoxonase activity modifies plasma lipid profile and paraoxonase has an antiatherogenic property. Non-selective beta-blockers affect plasma lipid profile too, but they have atherogenic property when patients take these drugs in long term. In this study the effect of propranolol, a non-selective beta-blocker, on paraoxonase activity was investigated. L...

Background and AimsWe aimed to perform a network meta-analysis (NWM) examine comparative effectiveness of non-selective beta blockers (NSBBs) on prophylaxis gastroesophageal variceal bleeding (GVB) mortality benefit.

Background Some studies indicate a reduced risk of serious upper gastrointestinal bleeding (UGIB) for users of beta-blockers, but the association remains to be confirmed in larger studies and characterized with respect to differences among beta-blockers. We aimed to assess whether beta-blocker use decreases the risk of UGIB. Methods We conducted a register-based, population-based case-control...

Objective: Beta-blockers are a group of drugs used in the treatment cardiovascular ailments. On other hand, potential anticancer effects these have become increasingly important recent two decades. In this paper, beta-1 selective esmolol, beta-2 ICI-118,551 and non-selective nadolol on breast cancer cell lines with different aggressiveness were investigated for first time. Methods: A standard s...

BaCkground Beta-blockers refer to an assorted group of medications that block the action of endogenous catecholamines on beta-adrenergic receptors. The β1 and β2 receptors are the primary beta-adrenergic receptors in the human cardiovascular system. Betablockers differ in their β1/β2-receptor selectivity and vasodilatory properties. Based on this diversity, beta-blockers have been categorised i...

Abstract Purpose of Review Our understanding beta blockers in liver cirrhosis has transformed over the last 40 years. However, questions remain their safety acute decompensation and on chronic failure. Since these conditions are associated with significant morbidity mortality, a critical appraisal recent literature is imperative to help guide clinicians. Recent Findings The latest BAVENO guidel...